OncoMatch/Clinical Trials/NCT06803680
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
Is NCT06803680 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments including BGB-B455 and Chemotherapy for advanced solid tumor.
Treatment: BGB-B455 · Chemotherapy — The goal of this clinical trial is to learn if BGB-B455 can treat advanced or metastatic solid tumors expressing claudin 6 (CLDN6), a protein that is found on some tumors. The main questions it aims to answer are: * What is the recommended dosing for BGB-B455? * What medical problems do participants have when taking BGB-B455? The study has two parts: * Phase 1a: dose escalation and safety expansion * Phase 1b: dose expansion
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Biomarker criteria
Required: CLDN6 expression (testing required; no eligibility threshold specified)
Performance status
ECOG 0–1(Restricted strenuous activity)
Stable Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
Prior therapy
Must have received: systemic therapy — advanced or metastatic disease
have previously received standard systemic therapy for advanced or metastatic disease or for whom treatment is not available or not tolerated
Lab requirements
Blood counts
Adequate organ function
Kidney function
Adequate organ function
Liver function
Adequate organ function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Adventhealth · Celebration, Florida
- Sidney Kimmel Cancer Center · Philadelphia, Pennsylvania
- Avera Cancer Institute · Sioux Falls, South Dakota
- Next Oncology · San Antonio, Texas
- Fred Hutchinson Cancer Research Center · Seattle, Washington
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06803680 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received systemic therapy.
Does this trial require CLDN6?
Yes, CLDN6 expression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify